Benign Skin TumorNCT06598137
Study to Examine Lesions of the Skin Using Confocal Laser Microscopy
An observational study of Benign Skin Tumor and Basal Cell Carcinoma, run by LMU Klinikum at 1 site in Germany.
Trial summary
Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Benign Skin Tumor, Basal Cell Carcinoma, Melanoma
- What is being tested?
- Ex vivo confocal laser microscopy
- Type of treatment
- Surgery or procedure
- How many people
- 645 participants
- Where
- 1 siteGermany
- Study dates
- 1 Feb 2024to 31 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients with benign and malignant skin tumors
Who may be able to join
- Patients with benign and malignant skin tumors
Who cannot join
- Patients unable to consent
Trial locations and contacts
1 site in 1 country.
Germany1 site
Clinic for Dermatology and Allergy LMU Munich
Munich, Bavaria, 80337
About this study
Official title: Multicenter, Prospective Study to Examine Pigmented, Non-pigmented, Tumorous and Inflammatory Lesions of the Skin With Regard to Cut Margin Control, Differentiation, Grading and Tumor Thickness Using Confocal Laser Microscopy
Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
Read the detailed description
Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
- Being tested
- Ex vivo confocal laser microscopy
- Medical subject headings
- Carcinoma, Basal Cell, Melanoma, Neoplasms, Squamous Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ex vivo confocal laser microscopyProcedure or surgery
Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
What is being measured
The primary outcome is the main question the study is designed to answer.
Reaching the planned number of patients >640
Reaching the planned number of patients \>640
Measured: approx. 1-4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start1 Feb 2024
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Benign Skin TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 645 participants (estimated)
Sponsor and investigators
- Lead sponsor
- LMU Klinikum
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maximilian Deußing, LMU Klinikum
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06598137
- Sponsor's protocol ID
- 23-0393
- Status last verified
- Aug 2026
- First submitted
- 11 Sep 2024
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multicenter, Prospective Study to Examine Pigmented, Non-pigmented, Tumorous and Inflammatory Lesions of the Skin With Regard to Cut Margin Control, Differentiation, Grading and Tumor Thickness Using Confocal Laser Microscopy
- ClinicalTrials.gov ID
- NCT06598137
- Acronym / sponsor ID
- 23-0393
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 645 participants (estimated)
- Lead sponsor
- LMU KlinikumUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
Detailed description
Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with benign and malignant skin tumors
Key inclusion criteria (1 listed)
- Patients with benign and malignant skin tumors
Key exclusion criteria (1 listed)
- Patients unable to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ex vivo confocal laser microscopyUsing ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations. | Procedure or surgery | – |
Primary outcome
Reaching the planned number of patients >640
Time frame: approx. 1-4 years
Reaching the planned number of patients \>640
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Benign Skin Tumor
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruiting
Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue
Breast Cancer
RecruitingPhase 3
Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin
Enrolling by invitation
Low-field MRI for Breast Cancer Screening
Breast Benign, Malignant Neoplasm of Breast
Recruiting
Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program
Skin Cancer, Skin Cancer Prevention
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Benign Skin Tumor and Basal Cell Carcinoma, run by LMU Klinikum at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reaching the planned number of patients >640 (time frame: approx. 1-4 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.